Discounted Cash Flow
Bioceres Crop Solutions Corp. Foreign
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2018 | $133.5m | $25.2m | $16.2m | 18.9% | — |
| 2019 | $160.6m (20.3%) | $-18.4m (-172.8%) | $27.2m (68.6%) | -11.4% (-160.5%) | $-0.60 |
| 2020 | $173.1m (7.8%) | $3.4m (118.3%) | $11.4m (-58.2%) | 1.9% (117.0%) | $0.09 (115.5%) |
| 2021 | $209.5m (21.0%) | $-6.9m (-304.5%) | $-9.7m (-185.2%) | -3.3% (-269.0%) | $-0.18 (-288.4%) |
| 2022 | $334.8m (59.8%) | $-7.2m (-4.8%) | $-21.3m (-119.3%) | -2.2% (34.4%) | $-0.17 (2.9%) |
| 2023 | $415.7m (24.2%) | $18.8m (360.8%) | $-408.2k (98.1%) | 4.5% (310.1%) | $0.30 (277.6%) |
| 2024 | $464.8m (11.8%) | $3.2m (-82.7%) | $41.0m (10140.8%) | 0.7% (-84.6%) | $0.05 (-82.9%) |
| 2025 | $335.1m (-27.9%) | $-55.4m (-1808.6%) | $49.0m (19.5%) | -16.5% (-2469.8%) | $-0.88 (-1798.4%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.